Partial epigenetic reprogramming

The ER-100 sponsor announced its first participant dosed in June 2026. The Phase 1 optic-neuropathy trial is evaluating safety and visual function.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Starting a clinical trial establishes rejuvenation or safety.

What the reviewed records say:

The gap: The reviewed announcement reports no clinical outcome results. Human efficacy, durability and long-term safety remain unestablished.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

The reviewed announcement reports no clinical outcome results. Human efficacy, durability and long-term safety remain unestablished.